Baidu
map

关注原发性免疫缺陷病(PID) 让爱不再罕见

2019-04-22 不详 美通社

原发性免疫缺陷病(PID)是由于先天因素或遗传因素导致免疫系统缺陷,机体抗感染免疫功能低下的一组临床病症。在过去的20多年中,已有354种 PID 被逐步发现,随着对免疫缺陷的研究不断深入,这个数字还在不断增加。估测我国累计 PID 患儿约有3-6万例,仅在上海复旦大学附属儿科医院,每年新确诊的 PID 就超过百例。持续增长的患儿数量,使得 PID 成为一种“不罕见的罕见病”。 签约启动仪式

原发性免疫缺陷病(PID)是由于先天因素或遗传因素导致免疫系统缺陷,机体抗感染免疫功能低下的一组临床病症。在过去的20多年中,已有354种 PID 被逐步发现,随着对免疫缺陷的研究不断深入,这个数字还在不断增加。估测我国累计 PID 患儿约有3-6万例,仅在上海复旦大学附属儿科医院,每年新确诊的 PID 就超过百例。持续增长的患儿数量,使得 PID 成为一种“不罕见的罕见病”。

签约启动仪式
签约启动仪式

 

然而,全社会对于 PID 的认知还非常有限,甚至一些医务工作者也并不了解,存在误区。结果导致不少 PID 患儿被当作普通感染来进行治疗,从而延误病情而影响治疗。为了提高公众对 PID 的认知,呼吁社会各界给予 PID 患者及家庭更多关注和支持,不断推动 PID 的临床诊疗和研究工作,在全球第五个“原发性免疫缺陷周”来临之际,复旦大学附属儿科医院, 北京医学奖励基金会、 中国儿童免疫与健康联盟与 BD(中国)共同发起了“PID 中国行”项目。复旦儿科医院作为“PID 中国行“首站,在国内首次发布“PID 公益宣传手册”。复旦大学附属儿科医院免疫科主任王晓川教授希望不仅给予 PID 患儿最好的治疗,更能通过不懈的努力和呼吁,让全社会了解 PID,帮助基层医生认识 PID,及早诊断 PID,呼吁社会各界给予 PID 患儿和家庭更多的关心、支持和帮助。

在全球第五个“原发性免疫缺陷周”来临之际,复旦大学附属儿科医院,北京医学奖励基金会、中国儿童免疫与健康联盟与BD(中国)共同发起了“PID中国行”项目。

北京医学奖励基金会顾问张晓玉院长表示:“少年强则中国强,儿童健康关系到千家万户的幸福和中华民族的未来,理应放在最重要的位置。中国儿童免疫与健康联盟是我国第一个以交叉学科联合治疗为手段,关注儿童疾病的预防、治疗、康复全程管理的医联体组织。由于免疫系统的先天性缺陷,PID 患儿的感染往往非常严重并且反复;而对某些 PID 患儿使用减毒活疫苗,则可能产生严重的不良反应。因此,如果不及早诊断 PID,不仅对患儿身心带来巨大的伤害,也会给家庭和社会造成沉重的经济负担。当下,提高全社会对 PID 的认知已经刻不容缓。此次启动PID 中国行就是希望动员学会、医院、社会各界的资源和力量,让 PID 患儿能够尽早得到专业的诊断和治疗,同时减轻公共卫生系统的负担。

为了进一步培养我国 PID 专业人员,加强同国外的合作交流,4月17日-19日“枫林国际临床免疫论坛”在上海举行,本次会议由中国儿童免疫与健康联盟、国家儿童医学中心复旦大学附属儿科医院主办。会议首先回顾了我国 PID 的发展历史,对在 PID 领域做出杰出贡献的老一辈专家颁发了“PID 先驱奖”,同时对在上一年度做出贡献的国内同行颁发了“PID 年度贡献奖”,老一辈的事迹激励着我们继续前进。同时,该会议邀请国内外相关领域顶尖专家,就当前 PID 领域的热点问题,如真菌感染的免疫问题、EBV 感染的免疫问题、疫苗接种的免疫问题等,进行了深入的交流。该会议让参会者开阔了视野,增长了知识,促进了相互间的合作。

防微杜渐 警惕原发性免疫缺陷病预警症状

由于 PID 早期的典型症状是反复、严重的感染(如肺部感染、中耳炎、持续皮肤真菌感染等),王晓川教授表示,及早发现 PID,及早对 PID 进行诊断治疗可以大大提高治愈的机会,减少并发症。随着医学发展,流式细胞术、基因检测以及干细胞移植等技术的成熟应用,越来越多的 PID 患儿获得了早期诊断和有效的治疗,完全有机会重返正常的健康生活。

“PID 的早期诊断对疾病的有效治疗和管理至关重要。这不仅需要提高临床医务工作者的诊疗水平,公众对于疾病的认识也必不可少。PID 的10大预警症状不仅为广大的儿科临床医生提供了预判 PID 的重要参考,也为公众提供了通俗易懂的判断方法。通过免疫功能检测可以早期诊断 PID,这使很多抗体缺陷病的患者通过定期输注静脉丙种球蛋白而控制疾病;有些患儿通过干细胞移植治疗更是得到根治的机会。 王晓川教授补充道。

在 4.20全球第5个 PID 关爱日活动上,复旦儿科医院作为“PID 中国行“的首站,首次发布“PID 公益宣传手册”,手册中提到 PID 的10大预警症状。王晓川教授强调,如出现两种或两种以上症状,就应该怀疑是否可能是 PID,应尽早前往免疫科咨询是否存在潜在的免疫缺陷病。十大预警症状包括:

1.  一年内4次或以上新发耳部感染(中耳炎)
2.  一年内2次或以上严重鼻窦感染
3.  使用抗生素2个月或更长时间收效甚微
4.  一年出现2次以上肺部感染
5.  婴儿体重不增或生长发育落后
6.  深度皮肤脓肿或器官脓肿反复发作
7.  持续性口腔鹅口疮或皮肤真菌感染
8.  需要静脉输注抗菌药物清除感染
9.  2次或以上深部感染,包括败血症
10.有原发性免疫缺陷家族史

第5届全球原发性免疫缺陷病纪念日现场互动
第5届全球原发性免疫缺陷病纪念日现场互动

复旦儿科医院自2014年以来,长期致力于 PID 患者慈善公益活动,临床免疫科侯佳医生介绍说,希望儿科医院不仅仅成为医疗诊治的平台,更希望成为 PID 患儿和家庭的社会支持平台。以全球 PID 日关爱活动为契机,希望更多的病友能够了解原发性免疫缺陷病,给医院和医护人员更多的信任,配合医护人员的诊断和治疗,“原发性免疫缺陷病是可治的”,要有信心、有勇气,和医护人员肩并肩共同努力来战胜疾病。

王晓川教授同时呼吁:“希望早日能够在预防接种过程中对高危群体进行免疫功能评估,这能大大降低 PID患儿发生疫苗不良反应的风险。”

为 PID 患儿撑起“爱的保护伞”                

此次“PID 中国行”项目,将多角度、多渠道、多形式对社会公众与专科医生进行全面覆盖。面对患者和公众,计划在包括复旦儿科医院在内的5家全国性儿童医院开展科普教育和联合义诊咨询活动,免费发放超过50000份“十大预警症状PID 宣传手册,指导家长在发现警告体征后带小朋友去医院接受规范的诊断和治疗。

此外,目前非免疫专科医生和基层医生在疾病相关诊断、治疗到后期管理方面与大城市、专科医院医生仍存在很大差距。在专业领域,免疫缺陷中国行项目将依托多年来“流式学院在儿科医生中打下的基础,进一步打通线上、线下平台和资源,一方面邀请国外专家分享国际上最前沿治疗理念和临床实践;另一方面,邀请国内专家深入讲解流式细胞术在临床免疫评估的应用理论和方法实践,进一步提高儿童免疫相关疾病的诊疗水平。今年计划在全国8个城市开展学术巡讲,培训超过2000名中青年儿科骨干。同时,通过网络学院组织 PID 知识竞赛、案例解读,预期将覆盖全国近万名儿科医生。同时,BD 还将协助中国儿童免疫与健康联盟在全国范围内建立 PID 患儿数据库,针对 PID 患儿家庭开展定期义诊咨询,帮助他们重建健康幸福生活。

BD 大中华区生物科学业务副总裁吕雯先生表示:“作为全球领先的医疗技术公司,BD 致力于通过改善医学发现、医疗诊断效果和护理质量引领世界健康。在免疫疾病领域,BD 运用先进流式技术和全球经验,不断推动疾病的治疗水平。此次与中国儿童免疫与健康联盟和复旦儿科医院联合开展‘免疫缺陷中国行’项目,也是希望集各方之合力,不断推进中国 PID 诊疗及公众认知水平,让更多患儿重获新生,这也是 BD 应尽的企业社会责任。

关于复旦大学附属儿科医院

复旦大学附属儿科医院创建于 1952年,系国家卫计委预算管理单位、三级甲等医院,是集医、教、研、防为一体的综合性儿童专科医院,国家级的儿童医学中心,全国儿科学重点学科、国家“211工程”和“985”工程建设单位,最早被国家授予儿科学硕士、博士学位授权点、临床医学博士后流动站。在中国医学科学院发布的中国医院科技竞争力排行榜、复旦大学发布的中国医院最佳专科声誉排行榜和北京大学发布的中国医院最佳临床学科排行榜,复旦大学附属儿科医院儿科学均名列第一,连续八次荣膺上海市文明单位。

复旦大学上海医学院儿科学系设在儿科医院,每年承担 12个专业400余名医学生的临床教学与实习培养;每年在读博士和硕士研究生200余名。医院拥有国家儿科和儿外科住院医师规范化培训基地以及13个上海市儿科亚专科医师培训基地,每年培养100余名住院医师和专科医师。医院每年培养长期进修学员250名,短期进修学员300名,至今已经为全国各地培养进修医生7000余名。每年举办50-60期国家级继续教育学习班。

关于 BD

BD 是一家全球化的医疗技术公司,通过改善医学发现方法、医疗诊断效果和护理质量以引领世界健康。 BD 关注并支持每位一线医务工作者,致力于通过研发创新技术、服务和解决方案,帮助患者改善临床治疗,并帮助医护人员改进临床流程。 BD 及其 65,000 名全球员工秉承高度的热情和信念,为临床医护人员提供安全、高效的护理给药流程,协助实验室科学家们更有效地诊断疾病,并提升科研人员研发新一代诊断及治疗疾病的能力。 BD 在几乎所有国家均设有分支机构,与全球范围内的组织机构积极合作,携手应对最具挑战的全球健康问题。通过与客户的紧密协作, BD 以改善治疗结果,降低医疗成本,提升诊断效率为己任,帮助加强患者和医护人员的安全并扩大医疗可及性。 2017 年, BD 欢迎巴德及其产品加入 BD 大家庭。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1846775, encodeId=55371846e7538, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Jun 04 21:54:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056753, encodeId=a0ec2056e53a3, content=<a href='/topic/show?id=19983e04485' target=_blank style='color:#2F92EE;'>#原发性免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37044, encryptionId=19983e04485, topicName=原发性免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Sun Jun 02 20:54:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365241, encodeId=3dc7365241ad, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/23/fa6ad39852b3fd26b8f7093d53c322a1.jpg, createdBy=807b5083691, createdName=用户被禁用, createdTime=Thu Apr 25 16:02:19 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467457, encodeId=f029146e4578b, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Apr 24 10:54:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488988, encodeId=3b5d148898837, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Wed Apr 24 10:54:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365153, encodeId=adcb3651535f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Apr 23 23:13:34 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365090, encodeId=7d1736509048, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Mon Apr 22 20:34:53 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1846775, encodeId=55371846e7538, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Jun 04 21:54:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056753, encodeId=a0ec2056e53a3, content=<a href='/topic/show?id=19983e04485' target=_blank style='color:#2F92EE;'>#原发性免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37044, encryptionId=19983e04485, topicName=原发性免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Sun Jun 02 20:54:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365241, encodeId=3dc7365241ad, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/23/fa6ad39852b3fd26b8f7093d53c322a1.jpg, createdBy=807b5083691, createdName=用户被禁用, createdTime=Thu Apr 25 16:02:19 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467457, encodeId=f029146e4578b, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Apr 24 10:54:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488988, encodeId=3b5d148898837, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Wed Apr 24 10:54:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365153, encodeId=adcb3651535f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Apr 23 23:13:34 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365090, encodeId=7d1736509048, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Mon Apr 22 20:34:53 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1846775, encodeId=55371846e7538, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Jun 04 21:54:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056753, encodeId=a0ec2056e53a3, content=<a href='/topic/show?id=19983e04485' target=_blank style='color:#2F92EE;'>#原发性免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37044, encryptionId=19983e04485, topicName=原发性免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Sun Jun 02 20:54:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365241, encodeId=3dc7365241ad, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/23/fa6ad39852b3fd26b8f7093d53c322a1.jpg, createdBy=807b5083691, createdName=用户被禁用, createdTime=Thu Apr 25 16:02:19 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467457, encodeId=f029146e4578b, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Apr 24 10:54:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488988, encodeId=3b5d148898837, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Wed Apr 24 10:54:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365153, encodeId=adcb3651535f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Apr 23 23:13:34 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365090, encodeId=7d1736509048, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Mon Apr 22 20:34:53 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
    2019-04-25 用户被禁用

    感谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1846775, encodeId=55371846e7538, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Jun 04 21:54:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056753, encodeId=a0ec2056e53a3, content=<a href='/topic/show?id=19983e04485' target=_blank style='color:#2F92EE;'>#原发性免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37044, encryptionId=19983e04485, topicName=原发性免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Sun Jun 02 20:54:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365241, encodeId=3dc7365241ad, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/23/fa6ad39852b3fd26b8f7093d53c322a1.jpg, createdBy=807b5083691, createdName=用户被禁用, createdTime=Thu Apr 25 16:02:19 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467457, encodeId=f029146e4578b, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Apr 24 10:54:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488988, encodeId=3b5d148898837, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Wed Apr 24 10:54:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365153, encodeId=adcb3651535f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Apr 23 23:13:34 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365090, encodeId=7d1736509048, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Mon Apr 22 20:34:53 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
    2019-04-24 syscxl
  5. [GetPortalCommentsPageByObjectIdResponse(id=1846775, encodeId=55371846e7538, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Jun 04 21:54:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056753, encodeId=a0ec2056e53a3, content=<a href='/topic/show?id=19983e04485' target=_blank style='color:#2F92EE;'>#原发性免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37044, encryptionId=19983e04485, topicName=原发性免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Sun Jun 02 20:54:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365241, encodeId=3dc7365241ad, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/23/fa6ad39852b3fd26b8f7093d53c322a1.jpg, createdBy=807b5083691, createdName=用户被禁用, createdTime=Thu Apr 25 16:02:19 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467457, encodeId=f029146e4578b, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Apr 24 10:54:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488988, encodeId=3b5d148898837, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Wed Apr 24 10:54:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365153, encodeId=adcb3651535f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Apr 23 23:13:34 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365090, encodeId=7d1736509048, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Mon Apr 22 20:34:53 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1846775, encodeId=55371846e7538, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Jun 04 21:54:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056753, encodeId=a0ec2056e53a3, content=<a href='/topic/show?id=19983e04485' target=_blank style='color:#2F92EE;'>#原发性免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37044, encryptionId=19983e04485, topicName=原发性免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Sun Jun 02 20:54:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365241, encodeId=3dc7365241ad, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/23/fa6ad39852b3fd26b8f7093d53c322a1.jpg, createdBy=807b5083691, createdName=用户被禁用, createdTime=Thu Apr 25 16:02:19 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467457, encodeId=f029146e4578b, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Apr 24 10:54:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488988, encodeId=3b5d148898837, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Wed Apr 24 10:54:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365153, encodeId=adcb3651535f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Apr 23 23:13:34 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365090, encodeId=7d1736509048, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Mon Apr 22 20:34:53 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
    2019-04-23 医者仁心5538

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1846775, encodeId=55371846e7538, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Jun 04 21:54:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056753, encodeId=a0ec2056e53a3, content=<a href='/topic/show?id=19983e04485' target=_blank style='color:#2F92EE;'>#原发性免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37044, encryptionId=19983e04485, topicName=原发性免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Sun Jun 02 20:54:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365241, encodeId=3dc7365241ad, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/23/fa6ad39852b3fd26b8f7093d53c322a1.jpg, createdBy=807b5083691, createdName=用户被禁用, createdTime=Thu Apr 25 16:02:19 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467457, encodeId=f029146e4578b, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Apr 24 10:54:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488988, encodeId=3b5d148898837, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Wed Apr 24 10:54:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365153, encodeId=adcb3651535f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Apr 23 23:13:34 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365090, encodeId=7d1736509048, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Mon Apr 22 20:34:53 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
    2019-04-22 王秀

    学习了,涨知识了!

    0

相关资讯

原发性免疫缺陷病抗感染治疗与预防专家共识

原发性免疫缺陷病(primary immunodeficiency,PID)典型临床表现为感染、自身免疫性疾病、自身炎症性疾病和肿瘤易感性增高,儿童期以感染为突出表现,常表现为反复、严重、持续性或条件致病菌感染。PID合并感染是临床的棘手问题,症状和体征不典型、病原菌和感染灶常难以确定、感染死亡率极高,给临床治疗带来困难。PID患儿急性感染期必须及时给予经验性抗感染治疗,部分PID患儿尚需积极采取

Blood:原发性免疫缺陷病成人患者进行异体造血干细胞移植可取得良好的预后。

原发性免疫缺陷病(PID),是罕见的遗传病,主要临床表现严重的免疫功能缺陷,目前可于儿童期通过同种异体造血干细胞移植(Allo-HSCT)治愈。由于缺乏经验和既往预后不良,现在对成年患者应用Allo-HSCT的最佳时间和具体方案尚存在争议。研究人员招募了29位成年患者,进行Allo-HSCT的平均年龄为24岁(17-50)。干细胞供体匹配或不匹配不相干(MUD/MMUD)(n=18),相关供体匹配

SCI REP:全国范围的原发性免疫缺陷病患者中严重且长期腹泻的研究

全国246例PIDs患者中26例(10.5%)患者,其中大部分为男性,在适当的预防性治疗前发展为SD表型。大多数病例是由沙门氏菌和假单胞菌感染引起的,需要IVIG和长期的抗生素治疗。早期认识和及时有效的抑制炎症的干预措施有利于降低RD表型的PIDs患者的死亡率。

Baidu
map
Baidu
map
Baidu
map